Intellectual Property India Publishes Patent Application for 'Fusion Protein Inhibitors Of Klk5' Filed by Biocryst Pharmaceuticals, Inc.

MUMBAI, India, May 9 -- Intellectual Property India has published a patent application (202517012234 A) filed by Biocryst Pharmaceuticals, Inc., Durham, U.S.A., on Feb. 13, for 'fusion protein inhibitors of klk5.'

Inventor(s) include Babu, Yarlagadda, S.; and Chen, Xilin.

The application for the patent was published on May 9, under issue no. 19/2025.

According to the abstract released by the Intellectual Property India: "Disclosed are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides...